These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 24927957)
1. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957 [TBL] [Abstract][Full Text] [Related]
2. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Pereira JR; Cheng R; Orlando M; Kim JH; Barraclough H Drugs R D; 2013 Dec; 13(4):289-96. PubMed ID: 24277116 [TBL] [Abstract][Full Text] [Related]
3. Increased lymphocyte to monocyte ratio is associated with better prognosis in patients with newly diagnosed metastatic nasopharyngeal carcinoma receiving chemotherapy. Lin GN; Peng JW; Liu DY; Xiao JJ; Chen YQ; Chen XQ Tumour Biol; 2014 Nov; 35(11):10849-54. PubMed ID: 25081376 [TBL] [Abstract][Full Text] [Related]
4. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458 [TBL] [Abstract][Full Text] [Related]
5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744 [TBL] [Abstract][Full Text] [Related]
6. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era. Ho CL; Lu CS; Chen JH; Chen YG; Huang TC; Wu YY Medicine (Baltimore); 2015 Jun; 94(24):e993. PubMed ID: 26091479 [TBL] [Abstract][Full Text] [Related]
7. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. Zhang GZ; Jiao SC; Meng ZT J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465 [TBL] [Abstract][Full Text] [Related]
8. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134 [TBL] [Abstract][Full Text] [Related]
9. Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients. Song YJ; Wang LX; Hong YQ; Lu ZH; Tong Q; Fang XZ; Tan J Tumour Biol; 2016 Apr; 37(4):5285-93. PubMed ID: 26561466 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216 [TBL] [Abstract][Full Text] [Related]
11. A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer. Yu H; Zhang J; Wu X; Luo Z; Wang H; Sun S; Peng W; Qiao J; Feng Y; Wang J; Chang J Cancer Biol Ther; 2014 Jul; 15(7):832-9. PubMed ID: 24755888 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy. Lin GN; Liu PP; Liu DY; Peng JW; Xiao JJ; Xia ZJ Chin J Cancer; 2016 Jan; 35():5. PubMed ID: 26740116 [TBL] [Abstract][Full Text] [Related]
13. Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all? Hashemi-Sadraei N; Pennell NA Curr Treat Options Oncol; 2012 Dec; 13(4):478-90. PubMed ID: 22972369 [TBL] [Abstract][Full Text] [Related]
14. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation. Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Absolute Lymphocyte Count, Absolute Monocyte Count, and Absolute Lymphocyte Count to Absolute Monocyte Count Ratio in Follicular Non-Hodgkin Lymphoma. Mohsen A; Taalab M; Abousamra N; Mabed M Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e606-e615. PubMed ID: 32303487 [TBL] [Abstract][Full Text] [Related]
16. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Standfield L; Weston AR; Barraclough H; Van Kooten M; Pavlakis N Respirology; 2011 Nov; 16(8):1210-20. PubMed ID: 21801275 [TBL] [Abstract][Full Text] [Related]
17. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659 [TBL] [Abstract][Full Text] [Related]
18. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Paz-Ares L; Mezger J; Ciuleanu TE; Fischer JR; von Pawel J; Provencio M; Kazarnowicz A; Losonczy G; de Castro G; Szczesna A; Crino L; Reck M; Ramlau R; Ulsperger E; Schumann C; Miziara JE; Lessa ÁE; Dediu M; Bálint B; Depenbrock H; Soldatenkova V; Kurek R; Hirsch FR; Thatcher N; Socinski MA; Lancet Oncol; 2015 Mar; 16(3):328-37. PubMed ID: 25701171 [TBL] [Abstract][Full Text] [Related]
19. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167 [TBL] [Abstract][Full Text] [Related]
20. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]